NanoBio Corporation, a biopharmaceutical company founded in 2000 has formed a new company, NanoCure Corporation. This strategic action is being taken to support the product development of the dendrimer-based drug delivery and imaging nanotechnology. Dendrimer drug delivery and imaging platforms are a nanotechnology developed at the University of Michigan Center for Biologic Nanotechnology and exclusively licensed to NanoBio Corporation.
This platform technology is based on nanometer-sized polymers called dendrimers. James R. Baker, Jr. CSO states, "The dendrimer technology, while at an early stage, could provide the basis for a whole new class of therapeutic compounds and imaging agents. We felt that the developmental process and business plans for this technology was unique and different from our nanoemulsion antimicrobial technology, and that warranted creation of the new commercialization entity. NanoBio is very optimistic that the dendrimer technology could be advanced to a first human clinic trial within 2 years."
Funded by contracts from the National Cancer Institute and the Michigan Life Sciences Corridor, NanoCure will develop unique cancer treatments based on dendrimer drug delivery that accomplish the long-sought goal to specifically treat cancer cells while avoiding the poisoning of healthy cells. Their small size enables them to escape the blood stream through vascular pores and selectively target and treat tumor cells. Dendrimers can also be programmed to simultaneously confirm the presence of cancer, analyze treatment efficacy and image tumors.
NanoBio Corporation's mission is to develop and commercialize topical and mucosal pharmaceuticals based on its patented antimicrobial nanoemulsion technology. NanoBio has in development pharmaceutical treatments for fungal, viral and bacterial infections of the skin and mucous membranes. NanoBio's products have important therapeutic, safety and cost advantages over currently available treatments.